{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:01:42Z","timestamp":1774976502426,"version":"3.50.1"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,8,27]],"date-time":"2012-08-27T00:00:00Z","timestamp":1346025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the frequency of lipid testing in clinical practice and to explore the relationship between rheumatoid arthritis (RA), dyslipidemia, and other cardiovascular (CV) risk factors with RA treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients in this retrospective database study were ages \u226518 years and had \u22652 physician diagnoses for RA or osteoarthritis (OA; comparator group) between March 2004 and March 2008. Outcomes of interest included the percentage of RA and OA patients receiving lipid tests, lipid profiles (total cholesterol, low\u2010density lipoprotein [LDL] cholesterol, and high\u2010density lipoprotein [HDL] cholesterol) of RA versus OA patients, and lipid profiles of RA patients before and after initiation with a tumor necrosis factor (TNF) inhibitor. We used multivariable regression to control potential confounders between the cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over a median \u22652\u2010year followup, fewer RA patients than OA patients had \u22651 lipid test (62.0% [95% confidence interval (95% CI) 61.5\u201362.5] versus 69.8% [95% CI 69.5\u201370.1]). Mean total cholesterol and LDL cholesterol were each 4 mg\/dl lower in the RA cohort (<jats:italic>P<\/jats:italic> &lt; 0.0001); HDL cholesterol was similar between the cohorts. Across the RA cohort, 25.2% of patients had suboptimal LDL cholesterol levels (\u2265130 mg\/dl). Among RA patients not receiving lipid\u2010lowering therapy who initiated TNF inhibitor therapy (n = 96), mean total cholesterol and LDL cholesterol increased by 5.4 and 4.0 mg\/dl, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with RA were less likely to be tested for hyperlipidemia and had more favorable lipid profiles than patients with OA. TNF inhibitor therapy modestly increased all lipid parameters. Additional studies are needed to determine the effect of traditional CV risk factors and inflammation and the impact of biologic agents on CV outcomes in RA patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.21693","type":"journal-article","created":{"date-parts":[[2012,4,13]],"date-time":"2012-04-13T15:51:39Z","timestamp":1334332299000},"page":"1282-1291","source":"Crossref","is-referenced-by-count":44,"title":["Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti\u2013tumor necrosis factor therapy"],"prefix":"10.1002","volume":"64","author":[{"given":"Jeffrey R.","family":"Curtis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ani","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Baser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,8,27]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20853"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20855"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2631"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.119404"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S2453"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.113696"},{"key":"e_1_2_8_8_2","first-page":"1701","article-title":"Lipid profiles in untreated patients with rheumatoid arthritis","volume":"26","author":"Park YB","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.9.842"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1952"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101964"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135871"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.051672"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S5178"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08213-2"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem089"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2383"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086728"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22809"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23281"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24040"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1405-7"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740500474578"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0702-2"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.09.004"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023119"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2005.05.010"},{"key":"e_1_2_8_29_2","first-page":"S531","article-title":"Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: analysis of five phase 3 clinical trials","volume":"58","author":"Genovese MC","year":"2008","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22033"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068064"},{"key":"e_1_2_8_32_2","first-page":"S731","article-title":"Long\u2010term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and a mean treatment duration of 2.4 years","volume":"60","author":"Van Vollenhoven RF","year":"2009","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_33_2","first-page":"544","article-title":"Safety of tocilizumab in patients with rheumatoid arthritis: analysis of median of 2.6 years of treatment in long\u2010tern extension studies","volume":"69","author":"Van Vollenhoven R","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24802"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2471"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar428"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-09-0274"},{"key":"e_1_2_8_38_2","volume-title":"Statistical abstract of the United States : 2000","year":"2000"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.059980"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.7.1121"},{"key":"e_1_2_8_41_2","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka T","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122226"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066191"},{"key":"e_1_2_8_44_2","first-page":"921","article-title":"Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Kiortsis DN","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.059691"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90016-G"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.21693","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.21693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:17:34Z","timestamp":1759418254000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.21693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,27]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/acr.21693"],"URL":"https:\/\/doi.org\/10.1002\/acr.21693","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,27]]}}}